Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma
This is a single-arm, multicenter, exploratory study to evaluate the efficacy and safety of AK104 in combination with cisplatin and paclitaxel in the treatment of resectable locally advanced esophageal squamous carcinoma.
Resectable Esophageal Squamous Cell Carcinoma|Neoadjuvant Therapy
DRUG: cadonilimab+chemotherapy
pathologic complete response (pCR), Analysis of prognosis efficacy of patients: pathologic complete response (pCR), 1 month after resection
Radical resection (R0), 1 month after resection|Overall survival(OS), up to 2 years|Objective response rate(ORR), After the start of drugs and before resection|Disease control rate(DCR), After the start of drugs and before resection|Disease-free survival(DFS), After resection and up to 2 years
This is a single-arm, multicenter, exploratory study to evaluate the efficacy and safety of AK104 in combination with cisplatin and paclitaxel in the treatment of resectable locally advanced esophageal squamous carcinoma.